Shingles Vaccine Market Report 2026

The shingles vaccine market size has grown rapidly in recent years. It will grow from $5.55 billion in 2025 to $6.37 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to limited availability of shingles vaccines, reliance on live attenuated vaccines, growing elderly population, increasing incidence of herpes zoster, rising awareness of immunization benefits.

The shingles vaccine market size is expected to see rapid growth in the next few years. It will grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to development of recombinant and subunit vaccines, expansion of public and private vaccination campaigns, increasing adoption of online and retail pharmacy distribution, rising government and healthcare initiatives for elderly immunization, integration of digital health monitoring for vaccination adherence. Major trends in the forecast period include rising adoption of recombinant and subunit shingles vaccines, increasing awareness of shingles prevention among older adults, expansion of vaccination programs through hospital and retail pharmacies, growth in online pharmacies and e-commerce vaccine distribution, focus on age-specific immunization strategies for 50+ population.

The expanding scope of vaccination programs is set to accelerate the shingles vaccine market ahead. Vaccination programs are structured public health efforts to deliver vaccines broadly, curbing infectious disease outbreaks. Their growth reflects heightened preventive health consciousness, spurring wider uptake to dodge illnesses. Vaccination programs boost shingles vaccine use by raising visibility and ease of access, suiting seniors and at-risk groups. They cut shingles odds and issues via prompt, broad shots, lifting community wellness. For example, in July 2025, the World Health Organization, a Switzerland-based global health body, noted first-dose human papillomavirus (HPV) vaccine coverage for girls climbed from 27% in 2023 to 31% in 2024. Thus, the rising vaccination programs are propelling the shingles vaccine market.

Leading companies in the shingles vaccine market are advancing novel formulas like recombinant adjuvanted vaccines to amplify immunity and ensure enduring shingles defense. Recombinant adjuvanted vaccines blend engineered viral elements with immune boosters for superior, prolonged shielding. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharma firm, introduced Shingrix, a shingles shot. This non-live, recombinant adjuvanted subunit vaccine goes in via two intramuscular doses for adults 50+, targeting shingles (herpes zoster) and its fallout, post-herpetic neuralgia. Boasting over 90% efficacy, it delivers robust, decade-plus protection, even for elderly or weakened immune systems.

In October 2023, GSK plc, a UK healthcare tech leader, joined forces with Chongqing Zhifei Biological Products Co. Ltd. for exclusive Shingrix distribution and promotion in China. This pact ramps Shingrix reach across 30,000+ sites while laying groundwork for co-building and selling GSK’s RSV vaccine (Arexvy) to Chinese seniors. Chongqing Zhifei Biological Products Co. Ltd. is a China biotech expert in crafting, making, and spreading cutting-edge vaccines.

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc.

North America was the largest region in the shingles vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the shingles vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the shingles vaccine market by increasing costs of imported vaccines, vaccine components, and cold chain logistics equipment. Segments like recombinant and subunit vaccines are most affected, particularly in regions like North America and Europe where import dependency is high. This has led to higher vaccine costs and potential supply delays. On the positive side, tariffs have encouraged local vaccine production, innovation in cold chain and distribution solutions, and improved domestic availability of shingles vaccines.

The shingles vaccine market research report is one of a series of new reports that provides shingles vaccine market statistics, including shingles vaccine industry global market size, regional shares, competitors with a shingles vaccine market share, detailed shingles vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the shingles vaccine industry. This shingles vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Shingles vaccine is a preventive immunization aimed at protecting against shingles (herpes zoster), a painful skin condition caused by the reactivation of the varicella-zoster virus. It stimulates the immune system to recognize and combat the virus, reducing the risk of developing shingles and its related complications.

The main types of shingles vaccines are live attenuated vaccines, recombinant vaccines, and subunit vaccines. A live attenuated vaccine contains a weakened form of the live pathogen that can replicate without causing disease, eliciting a strong and lasting immune response. Product examples include Shingrix, Zostavax, and SkyZoster, primarily administered to individuals aged 50-59 years, 60-69 years, and 70 years and above. These vaccines are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, clinics, and pharmacies.

The shingles vaccine market consists of sales of vaccine kits, cold chain storage equipment, pre-filled syringes, vaccine delivery devices, and temperature monitoring systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.